South Africa’s contraceptive shortage is not a supply chain accident. It is the predictable outcome of a structural vulnerability that civil society has been flagging for years, and a governance failure that deserves far more scrutiny than it is currently receiving.
Since early 2026, women across the country have struggled to access their monthly supply of oral contraceptives, following production disruptions at Aspen Pharmacare. Several widely used state-subsidised brands , Triphasil, Nordette, and Microval have had limited availability at clinics and pharmacies nationwide, as confirmed by the Department of Health. The trigger? Aspen’s East London-based oral contraceptive manufacturing facility was decommissioned in the first quarter of 2026. According to Aspen Pharmacare’s Senior Executive of Strategic Trade Development, Stavros Nicolaou, these products had simply become "economically unviable to continue producing."
That phrase economically unviable, should give us pause. The East London facility was not a recent investment. It was built and validated to European standards, with an estimated replacement cost of over R160 million, and had the capacity to produce between 24 and 30 million oral contraceptive packs per year. For decades, it anchored South Africa’s public sector contraceptive supply. Its quiet decommissioning, without any evident contingency plan for the 90-plus percent of demand it served in the public sector, raises uncomfortable questions about planning, accountability, and who bears the cost when a pharmaceutical giant restructures.
A Pattern the State Keeps Ignoring
Aspen’s response has been to pivot to imported branded alternatives , a transition requiring market authorisation from SAHPRA. While public sector supply has ostensibly been prioritised and "continues to be fully met," private sector patients face ongoing constraints pending regulatory approvals. That framing is generous. The reality on the ground, confirmed by Clicks, is that pharmacists are offering alternative equivalents, a far cry from the consistent, chosen contraception that women depend on for hormonal stability.
This is not South Africa’s first rodeo. A 2024 Stop Stockouts Project report, produced in partnership with Ritshidze, found that poor national procurement planning remains the primary driver of contraceptive stockouts and shortages, not isolated manufacturing events. Contributing factors include inaccurate demand forecasting, supplier manufacturing constraints, and late payments by provincial health operations. The 2017 collapse of the public sector injectable contraceptive contract produced nearly identical chaos: stockouts that persisted into 2019 and supply disruptions that cascaded across both public and private sectors. Researchers studying that episode recommended that countries incentivise manufacturers to register more than one factory as a supply source , precisely to insure against the kind of single-source collapse that South Africa is now experiencing again. The recommendation was never meaningfully institutionalised. Médecins Sans Frontières + 2
The Human Cost of Systemic Negligence
What makes the current crisis particularly troubling is the population it affects. Oral contraceptives are not lifestyle products , they are essential medicines for millions of women managing reproductive health, hormonal conditions, and in many cases, HIV-related health risks. As Dr. Indira Govender of the Rural Doctors Association has noted, "in the South African context where misogyny and gender-based violence are widespread, we cannot afford a deprioritisation of women’s sexual reproductive health issues." When women cannot access their contraceptive of choice, the cascading effects are significant: unintended pregnancies, hormonal disruption from switching methods, and the economic burden of travelling to multiple facilities or accessing private alternatives. Women forced onto alternatives may receive a one-month supply where they previously received two months, requiring an additional trip and additional cost, compounding the burden for those already on the margins.
Compare this to Kenya’s approach, where regulatory and marketing support was extended to manufacturers to expand supply diversity within the public sector. South Africa has the regulatory architecture, SAHPRA and the procurement infrastructure, but not the political will to enforce supply resilience as a non-negotiable condition of government contracts.
Accountability Starts With the State
Aspen, to be fair, is a private company operating on commercial logic. The harder question is why the South African state allowed a single domestic manufacturer to hold this much supply concentration for this long, with no viable redundancy plan. Supply security requires that countries investigate whether manufacturers can be required to register more than one factory as the source of supply. That is a regulatory and procurement decision, one that sits squarely with the government, not with Aspen.
The shortage will likely ease once SAHPRA processes the authorisation transfer. But the underlying vulnerability will remain entirely intact. Until South Africa treats contraceptive supply chain resilience as a constitutional obligation rather than a procurement afterthought, this will happen again.
Written by:
*Sesona Mdlokovana
Associate at BRICS+ Consulting Group
Africa Specialist
**The Views expressed do not necessarily reflect the views of Independent Media or IOL.
** MORE ARTICLES ON OUR WEBSITE https://bricscg.com/ (https://bricscg.com/)
** Follow @ (https://x.com/brics_daily)brics_daily (https://x.com/brics_daily)on Twitter for daily BRICS+ updates and instagram @brics_daily (https://www.instagram.com/brics_daily?igsh=bmhvbTd0YzA4a2wx)
